Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients

Polish Journal of Pathology

Volumn 62, Issue 1, 2011, Pages 31-40

  Klasa Mazurkiewicz, Dagmara ^a   Jarzab, Mirosław ^b   Milczek, Tomasz ^a   Lipińska, Barbara ^b   Emerich, Janusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Angiogenesis; Lymphangiogenesis; Ovarian cancer; Prognostic factors; VEGFR 2; VEGFR 3

Indexed keywords

TUMOR MARKER; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARIECTOMY; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KRUKENBERG TUMOR; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 79957947131     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006; 17: 181-187.
2. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transiton as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
3. Lenz HJ. Antiangiogenic agents in cancer therapy. Oncology 2005; 19: 1-11.
4. Achen MG, Stacker SA. Tumor lymphangiogenesis and metastatic spread - New players to emerge. Int J Cancer 2006; 119: 1755-1760.
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
6. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-478.
7. Ran S, Huang X, Downes A, Thorpe PE. Evaluation of novel antimouse VEGFR-2 antibodies as potential antiangiogenic of vascular targeting agents for tumor therapy. Neoplasia 2003; 5: 297-307.
8. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-3570.
9. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7: 462-468.
10. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-949.
11. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol 2007; 25: 4298-4307.
12. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactiva-tion of VEGFR-2. Cancer Res 2006; 66: 2650-2657.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Robinson ChJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-865.
15. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 1992; 52: 5738-5743.
16. Stacker SA, Achen MG. From anti-angiogenesis to anti-lym-phangiogenesis: emerging trends in cancer therapy. Lymphat Res Biol 2008; 6: 165-172.
17. Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006; 21: 857-865.
18. Liu L, Zhu D, Gao R, Guo H. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. Urol Int 2008; 81: 72-76.
19. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007; 37: 878-886.
20. Tsuchiya N, Sato K, Akao T, et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 2001; 195: 101-113.
21. Arita S, Kikkawa F, Kajiyama H, et al. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Int J Gynecol Cancer 2005; 15: 329-336.
22. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol 2005; 26: 81-87.
23. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006; 53: 91-96.
24. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795-799.
25. Büchler P, Reber HA, Büchler MW, et al. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 2002; 236: 738-749.
26. Ghosh S, Sullivan CA, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008; 39: 1835-1843.
27. Marioni G, Giacomelli L, DAlessandro E, et al. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD 105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. Anticancer Res 2008; 28 1B: 551-557.
28. Lin EY, Piepkorn M, Garcia R et al. Angiogenesis and vascular growth factor receptor expression in malignant melanoma. Plast Reconstr Surg 1999; 104: 1666-1674.
29. Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002; 118: 151-156.
30. Kato H, Yoshikawa M, Miyazaki T, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002; 22, 6C: 3977-3984.
31. Dales JP, Garcia S, Bonnier P, et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma]. Ann Pathol 2003; 23: 297-305.
32. Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006; 106: 1677-1684.
33. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
34. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74: 1105-1115.
35. Orre M, Lotfi-Miri M, Mamers P, Rogers PA. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. Br J Cancer 1998; 77: 2204-2209.
36. Inan S, Vatansever S, Celik-Ozenci C, et al. Immunolocaliza-tions of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 2006; 21: 1055-1064.
37. Nishida N, Yano H, Komai K, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004; 101: 1364-1374.
38. Witte D, Thomas A, Ali N, et al. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its lig-and VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002; 22: 1463-1466.
39. Li R Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58: 193-199.
40. Fielder W, Graeven U, Ergün S, et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997; 11: 1234-1237.
41. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003; 16: 652-659.
42. Clarijs R Schalkwijk L, Hofmann UB, et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 2002; 62: 7059-7065.
43. Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003; 201: 544-554.
44. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006; 9: 209-223.
45. Arinaga M, Noguchi T, Takeno S, et al. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003; 97: 457-464.
46. Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 2005; 104: 1668-1677.
47. Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathologi-cal and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 2007; 33: 294-300.
48. Jüttner S, Wissmann C, Jöns T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240.
49. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 2003; 9: 1361-1369.
50. Mouawad R Spano JP, Comperat E, et al. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome. Eur J Cancer 2009; 45: 1407-1414.
51. Li R Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58: 193-199.
52. Wang Z, Chen Y, Liang C, et al. Expression of VEGF-C and VEGFR-3 in human laryngeal squamous cell carcinomas and cervical metastatic lymph node tissues. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004; 18: 664-667.
53. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003; 88: 237-244.